ArticleInternational journal for parasitology. Drugs and drug resistance2012
Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis.
Article in International journal for parasitology. Drugs and drug resistance, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 104 citations in OpenAlex.
- New mercaptoacrylate derivatives and other constituents from the stem bark of Senegalia polyacantha: in vitro antioxidant and antiplasmodial activities with in silico target validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bio-guided identification of novel antiparasitic natural products from Gardenia imperialis K. Schum (Rubiaceae).Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Synthesis, Antiparasitic Activity and Substituent Effects of Methyl 5-(Hetero)aryl or Alicyclicaminothieno[2,3-Molecules (Basel, Switzerland) · 2026Article
- Osteoprotective Effects and In Silico Profiling of Parinari curatellifolia Planch. Ex Benth. (Chrysobalanaceae) Extract on Acute Plasmodium berghei-Compromised Rat Bone.Chemistry & biodiversity · 2026Article
- Evaluation of the Antimalarial Potential of a Combination ofJournal of parasitology research · 2026Article
- Potent kinase inhibitors from the Merck KGaA OGHL: Novel hits against Trypanosoma brucei with potential for repurposing.PLoS neglected tropical diseases · 2025Article
- Synthesis of Tricyclic and Tetracyclic Lactone Derivatives of Thieno[2,3-Molecules (Basel, Switzerland) · 2025Article
- Antiplasmodial Activity of a New Chemotype ofInternational journal of molecular sciences · 2025Article
- Toxicity Profile ofBiochemistry research international · 2025Article
- Protective and Ameliorative Effects of Hydroethanolic Extract ofJournal of toxicology · 2024Article
- High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents.Journal of medicinal chemistry · 2023Article
- Antiplasmodial and Antileishmanial Activities of a New Limonoid and Other Constituents from the Stem Bark ofMolecules (Basel, Switzerland) · 2023Article
- Article
- In vitro antiplasmodial activity and toxicological profile of extracts, fractions and chemical constituents of leaves and stem bark from Dacryodes edulis (Burseraceae).BMC complementary medicine and therapies · 2023Article
- Bromotyrosine-Derived Metabolites from a Marine Sponge InhibitInternational journal of molecular sciences · 2023Article
- Structure-Activity Relationships, Tolerability and Efficacy of Microtubule-Active 1,2,4-Triazolo[1,5-bioRxiv : the preprint server for biology · 2023Article
- Antiplasmodial, Antioxidant, and Cytotoxic Activity ofBioMed research international · 2023Article
- Preliminary Structure-Activity Relationship Study of the MMV Pathogen Box Compound MMV675968 (2,4-Diaminoquinazoline) Unveils Novel Inhibitors ofMolecules (Basel, Switzerland) · 2022Article
- Multitarget, Selective Compound Design Yields Potent Inhibitors of a Kinetoplastid Pteridine Reductase 1.Journal of medicinal chemistry · 2022Article
- In Vivo Efficacy of SQ109 againstBiomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human African trypanosomiasis (HAT) is caused by the protozoan parasite Trypanosoma brucei, and the disease is fatal if untreated. There is an urgent need to develop new, safe and effective treatments for HAT because current drugs have extremely poor safety profiles and are difficult to administer. Here we report the development and application of a cell-based resazurin reduction assay for high throughput screening and identification of new inhibitors of T. b. brucei as starting points for the development of new treatments for human HAT. Active compounds identified in primary screening of ∼48,000 compounds representing ∼25 chemical classes were titrated to obtain IC50 values. Cytotoxicity against a mammalian cell line was determined to provide indications of parasite versus host cell selectivity. Examples from hit series that showed selectivity and evidence of preliminary SAR were re-synthesized to confirm trypanocidal activity prior to initiating hit-to-lead expansion efforts. Additional assays such as serum shift, time to kill and reversibility of compound effect were developed and applied to provide further criteria for advancing compounds through the hit-to-lead phase of the project. From this initial effort, six distinct chemical series were selected and hit-to-lead chemistry was initiated to synthesize several key analogs for evaluation of trypanocidal activity in the resazurin-reduction assay for parasite viability. From the hit-to-lead efforts, a series was identified that demonstrated efficacy in a mouse model for T. b. brucei infection and was progressed into the lead optimization stage. In summary, the present study demonstrates the successful and effective use of resazurin-reduction based assays as tools for primary and secondary screening of a new compound series to identify leads for the treatment of HAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.